MX2013002784A - Heteroarilos fusionados y sus usos. - Google Patents

Heteroarilos fusionados y sus usos.

Info

Publication number
MX2013002784A
MX2013002784A MX2013002784A MX2013002784A MX2013002784A MX 2013002784 A MX2013002784 A MX 2013002784A MX 2013002784 A MX2013002784 A MX 2013002784A MX 2013002784 A MX2013002784 A MX 2013002784A MX 2013002784 A MX2013002784 A MX 2013002784A
Authority
MX
Mexico
Prior art keywords
fused heteroaryls
heteroaryls
fused
compositions
methods
Prior art date
Application number
MX2013002784A
Other languages
English (en)
Inventor
Weihan Zhang
Haibin Yang
Weiguo Su
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MX2013002784A publication Critical patent/MX2013002784A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Se proveen ciertos heteroarilo fusionados, composiciones de los mismos y métodos de uso de los mismos.
MX2013002784A 2010-09-16 2011-09-15 Heteroarilos fusionados y sus usos. MX2013002784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010076996 2010-09-16
PCT/CN2011/079684 WO2012034526A1 (en) 2010-09-16 2011-09-15 Fused heteroaryls and their uses

Publications (1)

Publication Number Publication Date
MX2013002784A true MX2013002784A (es) 2013-04-24

Family

ID=45831015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002784A MX2013002784A (es) 2010-09-16 2011-09-15 Heteroarilos fusionados y sus usos.

Country Status (12)

Country Link
US (1) US9181264B2 (es)
EP (1) EP2616468A4 (es)
JP (1) JP5634609B2 (es)
KR (1) KR20130087020A (es)
AU (1) AU2011301518B2 (es)
BR (1) BR112013005855A2 (es)
CA (1) CA2810708A1 (es)
MX (1) MX2013002784A (es)
NZ (1) NZ607527A (es)
RU (1) RU2552114C2 (es)
SG (1) SG188302A1 (es)
WO (1) WO2012034526A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011340167A1 (en) * 2010-12-06 2013-07-18 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
JP6189948B2 (ja) 2012-06-29 2017-08-30 ファイザー・インク ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン
ES2608395T3 (es) * 2013-01-23 2017-04-10 Astrazeneca Ab Compuestos químicos
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US10112945B2 (en) * 2014-07-14 2018-10-30 Advenchen Pharmaceuticals, Nanjing Ltd. Fused quinoline compunds as PI3K, mTOR inhibitors
ES2782113T3 (es) * 2015-07-11 2020-09-10 Advenchen Pharmaceuticals Llc Compuestos de quinolina fusionados como inhibidores de PI3K/mTor
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
EA201891439A1 (ru) * 2015-12-18 2018-12-28 Новартис Аг Трициклические соединения и их композиции в качестве ингибиторов киназ
JP7247092B2 (ja) * 2017-01-09 2023-03-28 上海瑛派▲薬▼▲業▼有限公司 キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途
KR102143320B1 (ko) 2018-08-28 2020-08-12 주식회사 스템랩 합성 메신저 rna를 이용하여 소변세포를 신경줄기세포로 직접 역분화하는 방법
CN109810112B (zh) * 2019-02-01 2021-03-23 华侨大学 一种吲哚并[2,1-a]酞嗪衍生物的制备方法
CN109912606B (zh) * 2019-04-16 2021-05-04 新乡医学院 一种嘧啶并吲唑类化合物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN160956B (es) * 1982-10-18 1987-08-22 Pfizer
DK0783504T3 (da) * 1994-09-16 2000-08-14 Novo Nordisk As (1,2,4)triazolo (4,3-a)guinoxalinon-derivater, deres fremstilling og anvendelse som antagonister af ampa-receptorer
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
CA2546117A1 (en) * 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
MX2008007864A (es) * 2005-12-16 2009-03-04 Coley Pharm Group Inc Imidazoquinolinas, imidazonaftiridinas, e imidazopiridinas sustituidas, composiciones y metodos.
CN101784547A (zh) * 2007-08-14 2010-07-21 诺瓦提斯公司 作为GABAα配体的吡唑并喹啉和吡唑并萘啶衍生物
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
JP5591809B2 (ja) * 2008-09-30 2014-09-17 ファイザー・インク イミダゾ［１，５］ナフチリジン化合物、その医薬への使用、および組成物
US20100078444A1 (en) 2008-09-30 2010-04-01 Thomas Gerard Shannon Compressed tissue product
WO2010054260A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
WO2010054253A1 (en) * 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
KR20120087936A (ko) * 2009-10-06 2012-08-07 선에시스 파마슈티컬스 인코포레이티드 Ｐｄｋ１ 저해제로서 유용한 헤테로시클릭 화합물
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease

Also Published As

Publication number Publication date
US20130190307A1 (en) 2013-07-25
RU2552114C2 (ru) 2015-06-10
BR112013005855A2 (pt) 2016-05-17
AU2011301518A1 (en) 2013-03-14
AU2011301518B2 (en) 2014-07-03
JP5634609B2 (ja) 2014-12-03
NZ607527A (en) 2015-04-24
US9181264B2 (en) 2015-11-10
EP2616468A1 (en) 2013-07-24
SG188302A1 (en) 2013-04-30
JP2013537204A (ja) 2013-09-30
WO2012034526A1 (en) 2012-03-22
EP2616468A4 (en) 2014-02-26
KR20130087020A (ko) 2013-08-05
CA2810708A1 (en) 2012-03-22
RU2013108348A (ru) 2014-10-27

Similar Documents

Publication Publication Date Title
MX2013002784A (es) Heteroarilos fusionados y sus usos.
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
IL250824B (en) Certain amino-pyrimidines, their assemblies, and methods of using them
HK1226068A1 (zh) 特定氨基-嘧啶、其組合物及其使用方法
EP4223770A3 (en) Novel fusion molecules and uses thereof
MY181898A (en) Heterocyclic compounds and uses thereof
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
GB201218752D0 (en) Mineral complex, compositions thereof, and methods of using the same
MY169141A (en) Biodegradable compositions, methods and uses thereof
IN2015DN00127A (es)
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
IN2014DN06166A (es)
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
MY161601A (en) Films and compositions comprising the same
MX358864B (es) Polipeptidos antibacterianos quimericos.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
WO2013155338A3 (en) Substituted benzamides and their uses
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
MX2013008559A (es) Derivados de leptina.
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства
UA41660U (en) Use of jacton and mexidol as actoprotector
UA72478U (ru) Применение полентара как средства фригопротекторного действия
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal